ARTICLE | Management Tracks
Avila joins Atea as SVP of medical affairs; plus Werewolf, Senda, Aurion, Sigilon and more
June 15, 2021 7:24 PM UTC
Viral infections company Atea Pharmaceuticals Inc. (NASDAQ:AVIR) hired Claudio Avila as SVP of medical affairs. Avila joins from Gilead Sciences Inc. (NASDAQ:GILD), where he was executive director of the U.S. medical strategy and medical affairs for COVID-19. He served as global program medical director for hepatitis B and C development at Novartis AG (NYSE:NVS; SIX:NOVN).
Werewolf Therapeutics Inc. (NASDAQ:HOWL) hired Chulani Karunatilake as CTO. Karunatilake joins the oncology play from Maverick Therapeutics Inc., where he was SVP of technical operations before the company’s acquisition by Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK) in March...